Compare Amgen, Inc. (AMGN) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs M&T Bank Corporation — how do they compare? Amgen, Inc. trades at $361.93 (market cap $196.12B), while M&T Bank Corporation trades at $244 (market cap $35.49B). The key difference: Amgen, Inc. is far larger — about 5.5× M&T Bank Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MTB | |
|---|---|---|
Market Cap | $196.12B | $35.49B |
Sector | Health | Financials |
52-Week High | $388.16 | $242.34 |
52-Week Low | $271.18 | $178.63 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
M&T Bank (MTB) trades at $242.34, up 1.85% with a bullish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $4.18 exceeding expectations. Fundamentals remain solid with a P/E of 13.61 and net income margin of 30.11%. Recent corporate actions include a $1.50 dividend payment scheduled for June 2026 and new board appointments supporting growth initiatives.
MTB presents a balanced investment case with strong profitability metrics and analyst consensus near current levels. The upcoming Q2 2026 earnings report on July 15 represents a key catalyst. Risks include negative cash flow trends and potential interest rate sensitivity. Institutional sentiment leans cautious with 62.5% hold ratings, suggesting measured optimism for the regional banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
